Phosphodiesterase 4 inhibitors and db-cAMP inhibit TNF-α release from human mononuclear cells. Effects of cAMP and cGMP-dependent protein kinase inhibitors

Mediators of Inflammation

Volumn 5, Issue 6, 1996, Pages 425-428

  Hichami, A ^a   Boichot, E ^a   Germain, N ^a   Berdyshev, E ^b   Coqueret, O ^c   Lagente, V ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

^b INSTITUTE OF MARINE BIOLOGY   (Russian Federation)

^c ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Cyclic AMP; cyclic GMP; Lipopolysaccharide; Mononuclear cells; Phosphodiesterase; Protein kinase A; Protein kinase G; TNF

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; BUCLADESINE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENZYME INHIBITOR; LIPOPOLYSACCHARIDE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0030444868     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/S0962935196000580     Document Type: Article

References (25)

1. Nicholson CD, Shahid M. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes-their potential utility in the therapy of asthma. Pulm Pharmacol 1994; 7: 1–17.
2. 2-adrenoceptor agonist, fenoterol. Eur Respir J 1996; 9: 220–225.
3. Beavo JA, Reifsnyder DK. Primary sequence of cyclic nucleotide phosphodiesterase isoenzymes and the design of selective inhibitors. Trends Pharmacol Sci 1990; 11: 150–155.
4. Beavo JA, Conti M, Heaslip RJ. Multiple cyclic nucleotide phosphodiesterase. Mol Pharmacol 1994; 46: 399–405.
5. Lincoln TM, Corbin JD. Characterization and biological role of the cGMP-dependent protein kinase. Adv Cyclic Nucleotide Res 1983; 15: 139–192.
6. Beavo JA, Bechtel PJ, Krebs EG. Activation of protein kinase by physiological concentrations of cyclic AMP: kinetics at high enzyme concentrations. Proc Natl Acad Sci USA 1974; 71: 3580–3583.
7. Jiang H, Shabb JB, Corbin JD. Cross-activation: overriding cAMP/cGMP selectivities of protein kinases in tissues. Biochem Cell Biol 1992; 70: 1283-1289.
8. Hichami A, Boichot E, Germain N, Legrand A, Moodley I, Lagente V. Involvement of cyclic AMP in the effects of phosphodiesterase IV inhibitors on arachidonate release from mononuclear cells. Eur J Pharmacol Mol Pharmacol section 1995; 291: 91–97.
9. Prabhakar U, Lipshutz D, O’Leary Bartus J, Slivjak MJ, Smith EF, Lee JC, Esser KM. Characterization of cyclic AMP-dependent inhibition of LPS-induced TNF-α production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int J Immunopharm 1994; 16: 805–816.
10. Molnar-Kimber KL, Yonno L, Heaslip RJ, Weichman BM. Differential regulation of TNF-α and IL-lß production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors. Med Inflamm 1992; 1: 411–417.
11. Semmler J, Wachtel H, Enders S. The specific type IV phosphodiesterase inhibitor rolipram supresses tumor necrosis factor-α production by human mononuclear cells. Int J Immunopharmacol 1993; 15: 409–413.
12. Verghese MW, McConnell RT, Strickland AB, Gooding RC, Stimpson SA, Yarnall DP, Taylor JD, Furdon PJ. Differential regulation of human monocyte-derived TNF-α and IL-lß by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J Pharmacol Exp Therap 1995; 272: 1313–1320.
13. Seldon PM, Barnes PJ, Meja K, Giembycz MA. Suppression of lipopolysaccharide-induced tumor necrosis factor-α generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol Pharmacol 1995; 48: 747–757.
14. Sinha B, Semmler J, Eisenhut T, Eigler A, Endres S. Enhanced tumor necrosis factor supression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol 1995; 25: 147–153.
15. Hichami A, Boichot E, Germain N, Coqueret O, Lagente V. Interactions between cAMP- and cGMP-dependent protein kinase inhibitors and phosphodiesterase 4 inhibitors on arachidonate release from human monocytes. Life Sci 1996; 59: PL255–PL261.
16. Hidaka H, Inagaki M, Kawamoto S, Sasaki Y. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 1984; 23: 5036–5041.
17. Chijiwa T, Mishima A, Hagiwara M, Sano M, Hayashi K, Inoue T, Naito K, Toshioka T, Hidaka H. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthetized selective inhibitor of cyclic-AMP-dependent protein kinase, N-[2- (p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H89), of PC12D pheochromocytoma cells. J Biol Chem 1990; 265: 5267–5272.
18. Butt E, Eigenthaler M, Genieser HG. (RP)-8-pCPT-cGMPs. A novel cGMP-dependent protein kinase inhibitor. Eur J Pharmacol – Mol Pharmacol section 1994; 269: 265–268.
19. Hallsworth MP, Giembycz MA, Barnes PJ, Lee TH. Cyclic AMP-elevating agents prolong or inhibit eosinophil survival depending on prior exposure to GM-CSE. Br J Pharmacol 1996; 117: 79–86.
20. Schmidt HH, Lohmann SM, Walter U. The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochem Biophys Acta 1993; 1178: 153–175.
21. Francis SH, Corbin JD. Structure and function of cyclic nucleotide-dependent protein kinases. Annu Rev Physiol 1994; 56: 237–272.
22. Torphy TJ, Freese W, Rinard GA, Brunton LL, Mayer SE. Cyclic nucleotide-dependent protein kinases in airway smooth muscle. J Biol Chem 1982; 257: 11609–11616.
23. Jiang H, Colbran JL, Francis SH, Corbin JD. Direct evidence for crossactivation of cGMP-dependent protein kinase by cAMP in pig coronary arteries. J Biol Chem 1992; 267: 1015–1019.
24. 2+ by cAMP in vascular smooth muscle cells. Am J Physiol 1990; 258: C399–C407.
25. Eckly AE, Stoclet JC, Lugnier C. Involvement of protein kinase G in vascular relaxation induced by the cyclic nucleotide phosphodiesterase IV inhibitor rolipram. Br J Pharmacol 1995; 114: 206P.